AnaptysBio Inc (NASDAQ:ANAB) currently has a daily average trading volume of 311.21K but it saw 1688471 shares traded in last market. With a market cap of 951.14M USD, the company’s current market price of $34.65 came rising about 3.96 while comparing to the previous closing price of $33.33. In past 52 weeks, the stock remained buoying in the range of price level as high as $38.85 and as low as $13.36. In the recent trading on the day, stock has struck highest price mark of $34.555 while lowest mark touched by it was $41.3083.
Taking a look at 20-day trading activity of AnaptysBio Inc (ANAB) gives us an average price of $34.49, while its current price level is -10.81% below from 52-week high level whereas it is 159.36% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $29.18 while that of 200 days or SMA-200 reads an average of $23.38. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.44% during that period while stretching the period over a month that decreases to 6.59%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.37 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the H.C. Wainwright which initiated the stock as “Buy” in its note to investors issued on July 22, 2024, recommending a price target of $55 for it. JP Morgan upgraded its recommendation for the stock as a “Overweight” from “Neutral” on July 19, 2024 while assigning a price target range of $29-$69. Leerink Partners also issued its recommendations for the stock as it initiated the price target for the stock is $47.
Over the week, ANAB’s stock price is moving 9.86% up while it is 0.49% when we observe its performance for the past one month. Year-to-date it is 61.76% up and over the past year, the stock is showing an upside performance of 79.72%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -1.41 beat the consensus estimate of -1.79 for the same. In next quarter, company is expected to be making quarterly sales of $7.03M as analysts are expecting the sales for current fiscal year at $31.99M and seeing the company making $28.44M in sales next year. Moreover, analysts are in estimates of $6.83M for current-quarter revenue.
Currently, AnaptysBio Inc’s total number of outstanding shares is 26.60M with 1.92% of that held by the insiders while 122.25% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -43.96% and return on equity (ROE) at -214.89%. Stock’s beta reads -0.28. Stock has a price to book (P/B) ratio of 96.22 while price to sale or P/S ratio amounts to 31.22. Its return on asset (ROA) is -36.02% on average.
